Helus Pharma tumbles as psychedelic trial suicide attempt rattles investors
HELP•Helus Pharma shares fell 10.5% after its late-stage HLP003 trial met its main goal, showing a 7.6-point placebo-adjusted improvement in depression symptoms at six weeks, but the company reported three treatment-related serious adverse events, including a suicide attempt.
1. Trial results and safety
Helus Pharma said HLP003 met the main goal of its late-stage study, delivering a 7.6-point placebo-adjusted improvement in depression symptoms at six weeks. The company reported three treatment-related serious adverse events among patients receiving the drug, including a suicide attempt by a patient who did not respond to treatment.
2. Analyst views
Barclays called the efficacy result “very strong” and cited management’s “reassuring safety context,” saying it saw “no fundamental reason” for the stock’s decline. Cantor said suicidal ideation or behavior is observed in this population and that it did not believe a single case established a safety signal; it called the share weakness “unwarranted.”




